Involvement of phosphodiesterases in autoimmune diseases

Keren Mizrachi, Revital Aricha, Tali Feferman, Neta Kela-Madar, Ilana Mandel, Tamar Paperna, Ariel Miller, Avraham Ben-Nun, Sonia Berrih-Aknin, Miriam C. Souroujon, Sara Fuchs

Research output: Contribution to journalArticlepeer-review


We have previously shown that several phosphodiesterase (PDE) subtypes are up-regulated in muscles and lymph node cells (LNC) of rats with experimental autoimmune myasthenia gravis (EAMG). In the present study we investigated PDE expression during the course of EAMG and experimental allergic encephalomyelitis (EAE) and found that the up-regulated expression of selected PDE subtypes in both experimental models is correlated with disease severity. In EAMG, PDE expression is correlated also with muscle damage. A similar up-regulation of PDE was also observed in the respective human diseases, MG and multiple sclerosis (MS). Our findings suggest that change in PDE expression levels is a general phenomenon in autoimmune diseases and may also be used as a marker for disease severity.

Original languageEnglish
Pages (from-to)43-51
Number of pages9
JournalJournal of Neuroimmunology
Issue number1-2
StatePublished - 30 Mar 2010

Bibliographical note

Funding Information:
Supported by grants from The Muscular Dystrophy Association of America (MDA) , The Association Francaise Contre les Myopathies (AFM) , The European Commission (MYASTAID , contract LSHM-CT-2006-037833 ) and The Chief Scientist Office, Israel Ministry of Health .


  • Experimental allergic encephalomyelitis (EAE)
  • Experimental autoimmune myasthenia gravis (EAMG)
  • Multiple sclerosis (MS)
  • Myasthenia gravis (MG)
  • Phosphodiesterases (PDE)


Dive into the research topics of 'Involvement of phosphodiesterases in autoimmune diseases'. Together they form a unique fingerprint.

Cite this